Key facts
- Blood’s last known valuation is $10.7M (Mar 2023).
- It has raised $2.9M; the latest was Later Stage VC in Feb 2025.
- Notable investors include DSG Consumer Partners, Accel-X, AngelCentral, Goldbell Investments, Quah De Yi.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Blood
- ·The full record, as it builds
Funding rounds
No funding rounds for Blood are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Blood
Manufacturer of pain relief patches intended to support women through their daily lives by creating innovative, data-backed products and insights. The company engages in providing pain relief patches for menstrual cramps, neck aches, backaches, and knee pains for females, along with an application that gives timely personalized health insights based on users' inputs, enabling women to support menstrual cramps.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Singapore, Singapore
- Founded
- 2014
- Employees
- 35
- Website
- getblood.com/
- Ownership
- Privately Held (backing)
Blood doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Blood shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Blood in its N-PORT filings yet. We sweep new filings monthly.